skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

“One pill, once daily”: what clinicians need to know about Atripla™

Review

(2356) Views  (400) Full article downloads

Authors: Patrick G Clay, Tracey AH Taylor, Alan G Glaros, MaryPeace McRae, Charlott Williams, et al

Published Date April 2008 Volume 2008:4(2) Pages 291 - 302
DOI: http://dx.doi.org/10.2147/TCRM.S1708

Patrick G Clay1,2, Tracey AH Taylor1, Alan G Glaros3, MaryPeace McRae1, Charlott Williams2, Don McCandless1, Maurice Oelklaus4

1Department of Pharmacology/Microbiology; 2Department of Clinical Research; 3Division of Basic Sciences; 4College of Medicine, Kansas City University of Medicine and Biosciences, Kansas City, MO, USA

Abstract: As the number of persons chronically prescribed antiretrovirals has grown and the realization that antiretrovirals are required to be continued for life, pharmaceutical manufacturers have developed new classes of agents, improved the pharmacokinetics of marketed products through dosing reformulations, and in an effort to maximize success with respect to adherence, compiled into a single dosing unit all necessary elements for an antiretroviral regimen. Atripla™ represents the first ever fixed-dose combination antiretroviral available. This article reviews currently available data on this agent, the impact of resistance on clinical use and implementation, as well as extensive descriptions of the pharmacokinetics, adverse effects and drug-interactions warranting consideration. Whether beginning in a naïve patient or switching from other regimens for tolerability issues, Atripla™ represents a viable option. Its demonstrated advantages with respect to lipid and hematologic parameters and equivalent incidence of renal toxicity are tempered by the findings of bone mineral density decreases, however. Combining multiple mechanisms of action in a single dosing unit appears to improve efficacy, increase the likelihood for adherence and maintain viral suppression compared to administering these agents independently. It is suggested other pharmaceutical companies assess the potential to replicate this for the remaining antiretrovirals.

Keywords: Atripla™, antiretrovirals, HIV








Readers of this article also read:

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec®, Gleevec™)
Cost-effectiveness analysis of electrochemotherapy with the Cliniporator™ vs other methods for the control and treatment of cutaneous and subcutaneous tumors
Docetaxel for the post-surgery treatment of patients with node-positive breast cancer
A review of nasal polyposis
Atripla™ – HIV therapy in one pill
Gemcitabine and taxanes in metastatic breast cancer: a systematic review
Tolvaptan and its potential in the treatment of hyponatremia
An update on the use of Atripla® in the treatment of HIV in the United States
Subgroup analysis of large trials can guide further research: a case study of vitamin E and pneumonia
Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden?